Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ruxolitinib phosphate
Find trials that include:  Any drugs shown
Results 1-25 of 29 for your search:
Start Over
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: MCC 17259, NCI-2013-00540, 12.12.0017, NCT01776723
Ruxolitinib Phosphate and Trastuzumab in Treating Patients with Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM1906, NCI-2014-02015, NCT02066532
Ruxolitinib Phosphate and Decitabine in Treating Patients with Myeloproliferative Neoplasms
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MPD-RC 109, NCI-2014-01264, GCO 13-1816, MPD-RC 107, NCT02076191
Ruxolitinib Phosphate and Decitabine in Treating Patients with Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0344, NCI-2014-02299, NCT02257138
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients with Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY007, NCI-2016-00203, NCT02713386
Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma following Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 283-11, NCI-2011-02733, 12C0196, NCT01431209
Ruxolitinib Phosphate in Treating Patients with Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-024, NCI-2012-00992, NCT01562873
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB18424-258, NCI-2011-03132, NCT01348490
Ruxolitinib Phosphate in Treating Patients With Adult T-Cell Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0006, NCI-2013-01560, 130006, 335354, P12996, NCT01712659
Ruxolitinib Phosphate and Exemestane in Treating Patients With Estrogen Receptor-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 02112, NCI-2012-00745, NCT01594216
Ruxolitinib Phosphate and Azacytidine in Treating Patients with Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0737, NCI-2013-00704, NCT01787487
Ruxolitinib Phosphate Before Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Myelofibrosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: MPD-RC 114, NCI-2014-01258, 12-00826, 12-1809, GCO 12-1809, NCT01790295
Ruxolitinib Phosphate in Treating Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB00010262, NCI-2014-00633, 10262, NCT02092324
Ruxolitinib Phosphate in Reducing Fatigue in Patients with Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 2013-0044, NCI-2014-01465, NCT02131584
JAK-2 Inhibitor before Donor Stem Cell Transplant in Treating Patients with Primary or Secondary Myelofibrosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9033, NCI-2014-01882, NCT02251821
Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 10 and over
Trial IDs: 2014-0521, NCI-2015-00779, NCT02420717
A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PRM-151G-101, NCI-2013-02329, NCT01981850
Ruxolitinib Phosphate and Pracinostat in Treating Patients with Myelofibrosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0445, NCI-2015-00002, NCT02267278
A Study With INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 to 70
Trial IDs: INCB 18424-204, NCI-2016-00599, NCT02553330
Ruxolitinib Phosphate and Nilotinib in Treating Patients with Chronic Myelogenous Leukemia
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17114, NCI-2013-00558, 12.09.0004, NCT01702064
Ruxolitinib Phosphate in Treating Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0012, NCI-2013-02204, NCT01895842
Ruxolitinib Phosphate, Dasatinib, and Dexamethasone in Treating Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 40 and over
Trial IDs: 14-272, NCI-2015-01173, NCT02494882
Start Over